The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome

Zhang C, Sarkar A, Wong E, Vaseghi M, Wang JJ. Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome.[...]

Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis

Repetti GG, Abel ED, Tontonoz P, Sallam T. Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis. Circ Res.[...]

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool

Jeanjean P, Swaidan A, Tse C, Kwock S, Fajnorova I, Dove R, Azrour IC, Taylor S, Comin-Anduix B, Nathanson DA, Carlucci G, Calais J, Czernin[...]